ReviewWorld journal of gastroenterology2016
Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells.JHEP reports : innovation in hepatology · 2026Article
- Prognostic Value of an Immune Long Non-Coding RNA Signature in Liver Hepatocellular Carcinoma.Journal of microbiology and biotechnology · 2024Article
- Diagnostic Performance of Extrahepatic Protein Induced by Vitamin K Absence in the Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.Clinical and molecular hepatology · 2022Review
- Identification of Potential Prognostic Markers and Key Therapeutic Targets in Hepatocellular Carcinoma Using Weighted Gene Co-Expression Network Analysis: A Systems Biology Approach.Iranian journal of biotechnology · 2022Article
- A robust gene expression signature for NASH in liver expression data.Scientific reports · 2022Article
- Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV.JHEP reports : innovation in hepatology · 2022Review
- Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C.Sovremennye tekhnologii v meditsine · 2021Article
- Bioinformatics analysis of key biomarkers and potential molecular mechanisms in hepatocellular carcinoma induced by hepatitis B virus.Medicine · 2020Article
- Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma.Infectious agents and cancer · 2020Article
- Review
- BiomarkersWorld journal of clinical cases · 2019Review
- Comprehensive investigation of key biomarkers and pathways in hepatitis B virus-related hepatocellular carcinoma.Journal of Cancer · 2019Article
- Biobanking for Viral Hepatitis Research.Frontiers in medicine · 2019Article
- Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.Alimentary pharmacology & therapeutics · 2018Observational
- Research gaps in viral hepatitis.Journal of the International AIDS Society · 2018Article
- Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma.Cancer management and research · 2018Article
- Differentially expressed genes of HepG2 cells treated with gecko polypeptide mixture.Journal of Cancer · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B virus (HBV) infected patients have an almost 100-fold increased risk to develop hepatocellular carcinoma (HCC). HCC is the fifth most common and third most deadly cancer worldwide. Up to 50% of newly diagnosed HCC cases are attributed to HBV infection. Early detection improves survival and can be achieved through regular screening. Six-monthly abdominal ultrasound, either alone or in combination with alpha-fetoprotein serum levels, has been widely endorsed for this purpose. Both techniques however yield limited diagnostic accuracy, which is not improved when they are combined. Alternative circulating or histological markers to predict or diagnose HCC are therefore urgently needed. Recent advances in systems biology technologies have enabled the identification of several new putative circulating biomarkers. Although results from studies assessing combinations of these biomarkers are promising, evidence for their clinical utility remains low. In addition, most of the studies conducted so far show limitations in design. Attention must be paid for instance to different ethnicities and different etiologies when studying biomarkers for hepatocellular carcinoma. This review provides an overview on the current understandings and recent progress in the field of diagnostic and predictive circulating biomarkers for hepatocellular carcinoma in chronically infected HBV patients and discusses the future prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.